Xlife Sciences AG: Successful capital raising of six million Swiss francs
DGAP-News: Xlife Sciences AG
/ Key word(s): Capital Increase
Capial increase of Xlife Sciences AG
Successful capital raising of six million Swiss francs
Xlife Sciences AG has successfully closed its capital increase and raised a total of 6.02 million Swiss Francs of new capital as of December 3, 2020. The placement was oversubscribed at the end of the subscription period. The management of the company sees the strong demand as a confirmation for its business model. The capital will be used almost exclusively for existing and new projects.
In the capital round completed on December 3, 2020, existing and new investors subscribed for shares with a total value of CHF 6.02 million. For Oliver R. Baumann, CEO of Xlife Sciences AG, the high demand of investors is a confirmation of the successful business model. "The strong interest of investors shows that our company, with its strategy of holding and developing a broad portfolio of early-stage life science projects is an attractive investment even in challenging times such as the corona crisis". Investors who are already invested in the life sciences sector consider the business model of Xlife as an attractive investment stage diversification, Baumann continues.
About Xlife Sciences AG
For media inquiries
04.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Frankfurt, Munich|
|EQS News ID:||1152688|
|End of News||DGAP News Service|